阿替利珠单抗联合维莫非尼和考比替尼治疗伴中枢神经系统转移的黑色素瘤患者(TRICOTEL):一项多中心、开放标签、单臂、2期研究
TRICOTEL研究在21家医院纳入BRAFV600突变阳性队列65例和野生型队列15例(因早期关闭),评估阿替利珠单抗联合考比替尼或维莫非尼+考比替尼治疗伴CNS转移的黑色素瘤。主要终点颅内客观缓解率在突变阳性队列按IRC评估为42%(95%CI 29-54),野生型队列按研究者评估为27%(95%CI 8-55)。作者认为在BRAFV600突变患者中联合方案显示有前景的颅内活性。
要点
- BRAFV600突变阳性队列颅内客观缓解率按IRC评估为42%(95%CI 29-54)。
- BRAFV600野生型队列因早期关闭,颅内客观缓解率按研究者评估为27%(95%CI 8-55)。
- 突变阳性队列治疗相关≥3级不良事件发生于41/60例(68%),野生型队列8/15例(53%)。
核心结论
- 在BRAFV600突变型黑色素瘤伴CNS转移患者中,阿替利珠单抗联合维莫非尼和考比替尼提供了有前景的颅内活性。
研究设计与样本
- TRICOTEL是一项在巴西、法国、德国、匈牙利、意大利、西班牙和瑞士21家医院和肿瘤中心开展的多中心、开放标签、单臂、2期研究,设BRAFV600野生型队列和BRAFV600突变阳性队列。
- 纳入年龄≥18岁、既往未治疗转移性黑色素瘤、至少一个维度CNS转移灶≥5 mm、ECOG体能状态≤2的患者。
- BRAFV600野生型队列接受静脉阿替利珠单抗840 mg(每28天周期第1、15天)联合口服考比替尼60 mg每日一次(第1-21天)。
- BRAFV600突变阳性队列接受静脉阿替利珠单抗840 mg(每28天周期第1、15天)联合口服维莫非尼720 mg每日两次和口服考比替尼60 mg每日一次(第1-21天),第1周期暂停阿替利珠单抗。
- 主要终点为经独立评审委员会(IRC)按改良RECIST 1.1评估、间隔至少4周确认的颅内客观缓解率;因野生型队列早期关闭,该队列主要终点未按IRC评估进行,改为报告研究者评估的颅内客观缓解率。
主要发现
- 2018年12月13日至2020年12月7日,BRAFV600突变阳性队列入组65例患者;BRAFV600野生型队列入组15例后早期关闭。
- BRAFV600突变阳性队列中位随访9.7个月(IQR 6.3-15.0),BRAFV600野生型队列中位随访6.2个月(IQR 3.5-23.0)。
- BRAFV600突变阳性队列按IRC评估的颅内客观缓解率为42%(95%CI 29-54),BRAFV600野生型队列按研究者评估的颅内客观缓解率为27%(95%CI 8-55)。
- BRAFV600突变阳性队列接受阿替利珠单抗+维莫非尼+考比替尼的60例中,41例(68%)发生治疗相关≥3级不良事件,最常见为脂肪酶升高(15/60例,25%)和血肌酸磷酸激酶升高(10/60例,17%)。
- BRAFV600野生型队列接受阿替利珠单抗+考比替尼的15例中,8例(53%)发生治疗相关≥3级不良事件,最常见为贫血(2/15例,13%)和痤疮样皮炎(2/15例,13%);治疗相关严重不良事件在突变阳性队列为14/60例(23%),野生型队列为2/15例(13%);突变阳性队列1例死亡(边缘叶脑炎)被认为与阿替利珠单抗治疗相关。
临床怎么用
- 作者认为,在BRAFV600突变型黑色素瘤伴CNS转移患者中,阿替利珠单抗联合维莫非尼和考比替尼提供了有前景的颅内活性。
局限性
- BRAFV600野生型队列因早期关闭,主要终点颅内客观缓解率未按IRC评估进行,改为报告研究者评估的颅内客观缓解率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. METHODS: TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland. Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less. Patients in the BRAFV600 wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21). Patients in the BRAFV600 mutation-positive cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral vemurafenib (720 mg twice daily) plus oral cobimetinib (60 mg once daily, days 1-21); atezolizumab was withheld in cycle 1. Treatment was continued until progression, toxicity, or death. The primary outcome was intracranial objective response rate confirmed by assessments at least 4 weeks apart, as assessed by independent review committee (IRC) using modified Response Evaluation Criteria in Solid Tumours version 1.1. Because of early closure of the BRAFV600 wild-type cohort, the primary endpoint of intracranial objective response rate by IRC assessment was not done in this cohort; intracranial objective response rate by investigator assessment was reported instead. Efficacy and safety were analysed in all patients who received at least one dose of study medication. This trial is closed to enrolment and is registered with ClinicalTrials.gov, NCT03625141. FINDINGS: Between Dec 13, 2018, and Dec 7, 2020, 65 patients were enrolled in the BRAFV600 mutation-positive cohort; the BRAFV600 wild-type cohort was closed early after enrolment of 15 patients. Median follow-up was 9·7 months (IQR 6·3-15·0) for the BRAFV600 mutation-positive cohort and 6·2 months (3·5-23·0) for the BRAFV600 wild-type cohort. Intracranial objective response rate was 42% (95% CI 29-54) by IRC assessment in the BRAFV600 mutation-positive cohort and 27% (95% CI 8-55) by investigator assessment in the BRAFV600 wild-type cohort. Treatment-related grade 3 or worse adverse events occurred in 41 (68%) of 60 patients who received atezolizumab plus vemurafenib plus cobimetinib in the BRAFV600 mutation-positive cohort, the most common of which were lipase increased (15 [25%] of 60 patients) and blood creatine phosphokinase increased (ten [17%]). Eight (53%) of 15 patients treated with atezolizumab plus cobimetinib in the BRAFV600 wild-type cohort had treatment-related grade 3 or worse adverse events, most commonly anaemia (two [13%]) and dermatitis acneiform (two [13%]). Treatment-related serious adverse events occurred in 14 (23%) of 60 patients in the BRAFV600 mutation-positive cohort and two (13%) of 15 in the BRAFV600 wild-type cohort. One death in the BRAFV600 mutation-positive cohort (limbic encephalitis) was considered to be related to atezolizumab treatment. INTERPRETATION: Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS metastases. FUNDING: F Hoffmann-La Roche.
引用
- Dummer R, Queirolo P, Abajo Guijarro AM, et al. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2022. PMID: 35940183. doi:10.1016/S1470-2045(22)00452-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。